| 词条 | Belinostat |
| 释义 |
| IUPAC_name = (2E)-N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide | image = Belinostat.svg | alt = | caption = | tradename = Beleodaq | Drugs.com = {{Drugs.com|parent|beleodaq}} | MedlinePlus = | pregnancy_AU = | pregnancy_US = D | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Intravenous (IV) | bioavailability = 100% (IV) | protein_bound = 92.9–95.8%[1] | metabolism = UGT1A1 | onset = | elimination_half-life = | excretion = Urine | CAS_number = 866323-14-0 | CAS_number_Ref = {{cascite|changed|??}} | ATCvet = | ATC_prefix = L01 | ATC_suffix = XX49 | PubChem = 6918638 | DrugBank = | ChemSpiderID = 5293831 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | UNII = F4H96P17NZ | UNII_Ref = {{fdacite|correct|FDA}} | ChEMBL = 408513 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEBI = 61076 | ChEBI_Ref = {{ebicite|correct|EBI}} | synonyms = PXD101 | KEGG = D08870 | C=15|H=14|N=2|O=4|S=1 | molecular_weight = 318.348 g/mol | smiles = O=S(=O)(Nc1ccccc1)c2cc(\\C=C\\C(=O)NO)ccc2 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+ | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = NCNRHFGMJRPRSK-MDZDMXLPSA-N }}Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.[2] It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.[3] In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer.[3] Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging.[4] Belinostat has been granted orphan drug and fast track designation by the FDA,[5] and was approved in the US for the use against peripheral T-cell lymphoma on 3 July 2014.[6] It is not approved in Europe {{as of|2014|8|lc=on}}.[7] The approved pharmaceutical formulation is given intravenously.[8]{{rp|180}} Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1*28 allele.[8]{{rp|179 and 181}} References1. ^{{cite web|title=Beleodaq (belinostat) For Injection, For Intravenous Administration. Full Prescribing Information|url=http://www.beleodaq.com/downloads/Final_Beleodaq_PI.pdf|publisher=Spectrum Pharmaceuticals, Inc. Irvine, CA 92618|accessdate=21 November 2015}} {{Intracellular chemotherapeutic agents}}{{HDAC inhibitors}}{{antineoplastic-drug-stub}}2. ^{{Cite journal |author1=Plumb JA |author2=Finn PW |author3=Williams RJ |display-authors=etal | title = Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101 | journal = Molecular Cancer Therapeutics | year = 2003 | volume = 2 | issue = 8 | pages = 721–728 | pmid = 12939461}} 3. ^{{cite news |url=http://www.biospace.com/news_story.aspx?NewsEntityId=75000 |title=CuraGen Corporation (CRGN) and TopoTarget A/S Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference |date=October 2007}} 4. ^{{citation |url=http://ash.confex.com/ash/2009/webprogram/Paper20945.html |title= Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma |date=December 2009}} 5. ^{{cite news |url=http://www.fiercebiotech.com/story/spectrum-adds-cancer-pipeline-350m-deal/2010-02-02#ixzz0fBunZz8B |title=Spectrum adds to cancer pipeline with $350M deal. |date=February 2010}} 6. ^1 {{cite news|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.htm|publisher=FDA|title=FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma|date=3 July 2014}} 7. ^{{cite journal | author = H. Spreitzer | date = 4 August 2014 | title = Neue Wirkstoffe – Belinostat | journal = Österreichische Apothekerzeitung | issue = 16/2014 | pages = 27 | language = German }} 8. ^1 {{cite book |last1=Lexicomp |first1= (corporate author) |editor-last=Bragalone |editor-first=DL |edition=14th|title=Drug Information Handbook for Oncology|publisher=Wolters Kluwer |date=2016 |isbn=9781591953517 }} 4 : Acrylamides|Histone deacetylase inhibitors|Sulfonamides|Hydroxamic acids |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。